1. Home
  2. SSP vs GBIO Comparison

SSP vs GBIO Comparison

Compare SSP & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo E.W. Scripps Company (The)

SSP

E.W. Scripps Company (The)

HOLD

Current Price

$3.96

Market Cap

395.2M

Sector

Industrials

ML Signal

HOLD

Logo Generation Bio Co.

GBIO

Generation Bio Co.

HOLD

Current Price

$5.55

Market Cap

36.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSP
GBIO
Founded
1878
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
395.2M
36.3M
IPO Year
1988
2020

Fundamental Metrics

Financial Performance
Metric
SSP
GBIO
Price
$3.96
$5.55
Analyst Decision
Buy
Buy
Analyst Count
2
5
Target Price
$5.50
$8.88
AVG Volume (30 Days)
986.5K
60.0K
Earning Date
11-06-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,318,706,000.00
$15,270,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$9.11
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.36
$3.00
52 Week High
$4.98
$12.40

Technical Indicators

Market Signals
Indicator
SSP
GBIO
Relative Strength Index (RSI) 45.61 58.47
Support Level $3.88 $5.20
Resistance Level $4.98 $5.70
Average True Range (ATR) 0.35 0.23
MACD -0.14 0.04
Stochastic Oscillator 7.24 81.00

Price Performance

Historical Comparison
SSP
GBIO

About SSP E.W. Scripps Company (The)

The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: